Failure of SCID-X1 gene therapy in older patients.
Gene therapy has been shown to be a highly effective treatment for infants with typical X-linked severe combined immunodeficiency (SCID-X1, gammac-deficiency). For patients in whom previous allogeneic transplantation has failed, and others with attenuated disease who may present later in life, the optimal treatment strategy in the absence of human leukocyte antigen (HLA)-matched donors is unclear. Here we report the failure of gene therapy in 2 such patients, despite effective gene transfer to bone marrow CD34(+) cells, suggesting that there are intrinsic host-dependent restrictions to efficacy. In particular, there is likely to be a limitation to initiation of normal thymopoiesis, and we therefore suggest that intervention for these patients should be considered as early as possible.
Thrasher
Adrian J
AJ
Molecular Immunology Unit, Institute of Child Health, London, United Kingdom.
Hacein-Bey-Abina
Salima
S
Gaspar
H Bobby
HB
Blanche
Stephane
S
Davies
E Graham
EG
Parsley
Kathryn
K
Gilmour
Kimberly
K
King
Douglas
D
Howe
Steven
S
Sinclair
Joanna
J
Hue
Christophe
C
Carlier
Frédérique
F
von Kalle
Christof
C
de Saint Basile
Geneviève
G
le Deist
Françoise
F
Fischer
Alain
A
Cavazzana-Calvo
Marina
M
D000328:Adult; D018952:Antigens, CD34; D001854:Bone Marrow Cells / Q000378:metabolism; D016026:Bone Marrow Transplantation; D040181:Genetic Diseases, X-Linked / Q000628:therapy*; D015316:Genetic Therapy; D006801:Humans; D008297:Male; D016511:Severe Combined Immunodeficiency / Q000628:therapy*; D014161:Transduction, Genetic; D017211:Treatment Failure
D018952:Antigens, CD34